knowledge -WSS

knowledge

author：fashion 2025-09-30 14:08:09 - browse：5

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： The EPA's new lead rule: How one expert crunched the numbers

WSS

Wearables generate powerful data but its not useful to doctors, yet

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

ReNAgade cuts staff seven months after raising $300 million

ReNAgade cuts staff seven months after raising $300 million

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Disappointing trial forces Pfizer to pivot on obesity medicine plans

focus

knowledge

explore

Novavax promises a turnaround & Lilly roils the obesity market

Disappointing trial forces Pfizer to pivot on obesity medicine plans

After affirmative action ruling, medical educators look to 'holistic review'

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Guidelines to prevent youth baseball injuries need more muscle

ReNAgade cuts staff seven months after raising $300 million

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Venture capitalist Bob Kocher on the state of digital health

Supreme Court strikes down use of affirmative action

Wearables generate powerful data but its not useful to doctors, yet

leisure time

U.K. Biobank has 500,000 peoples' genome sequences available

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

HIV vaccine remains elusive. Immunologists keep trying new ideas

It's time to retire 'poor historian' from clinicians' vocabularies

Rep. Raul Ruiz on the physician shortage and more

CDC director unscathed in first congressional testimony

hotspot

explore

knowledge

hotspot